Background Effect of fish oil supplementation on flow-mediated dilation, an index of endothelial function in humans, remains controversial. We performed a meta-analysis to determine whether fish oil supplementation could improve endothelial function. Methods Human intervention studies were identified by systematic searches of Medline, Embase, Cochrane's library and references of related reviews and studies. A random-effect model was applied to estimate the pooled results. Meta-regression and subgroup analyses were performed to evaluate the impact of study characteristics on the effect of fish oil supplementation on flow-mediated dilation. Results A total of sixteen records with 1,385 subjects were reviewed. The results of the pooled analysis showed that fish oil supplementation significantly improved flow-mediated dilation (weighed mean difference: 1.49%, 95% confidence interval 0.48% to 2.50%, p = 0.004). Meta-regression and subgroup analysis suggested that the quality of included studies were inversely related to the overall effect (regression coefficient = ？1.60, p = 0.04), and the significance of the effect was mainly driven by the studies with relatively poor quality. Sensitivity analysis including only double-blind, placebo-controlled studies indicated fish oil supplementation has no significant effect on endothelial function (weighed mean difference: 0.54%, 95% confidence interval ？0.25% to 1.33%, p = 0.18). Besides, normoglycemic subjects or participants with lower diastolic blood pressure seemed to be associated with remarkable improvement of endothelial function after fish oil supplementation. Conclusions Although current evidence suggested a possible role of fish oil in improving endothelial function, large-scale and high-quality clinical trials are needed to evaluate these effects before we can come to a definite conclusion.
References
[1]
Mozaffarian D, Rimm EB (2006) Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296: 1885–1899.
[2]
Lavie CJ, Milani RV, Mehra MR, Ventura HO (2009) Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 54: 585–594.
[3]
Mozaffarian D, Wu JH (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58: 2047–2067.
[4]
De Caterina R (2011) n-3 fatty acids in cardiovascular disease. N Engl J Med 364: 2439–2450.
[5]
Witte DR, Westerink J, de Koning EJ, van der Graaf Y, Grobbee DE, et al. (2005) Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations? J Am Coll Cardiol 45: 1987–1993.
[6]
Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, et al. (2009) Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 120: 502–509.
[7]
Inaba Y, Chen JA, Bergmann SR (2010) Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 26: 631–640.
[8]
Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G (2011) Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension 57: 363–369.
[9]
Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, et al. (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39: 257–265.
[10]
Bots ML, Westerink J, Rabelink TJ, de Koning EJ (2005) Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 26: 363–368.
[11]
Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, et al. (2011) Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 300: H2–12.
[12]
Anderson JS, Nettleton JA, Herrington DM, Johnson WC, Tsai MY, et al. (2010) Relation of omega-3 fatty acid and dietary fish intake with brachial artery flow-mediated vasodilation in the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 92: 1204–1213.
[13]
Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, et al. (2003) Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 166: 85–93.
[14]
Dyerberg J, Eskesen DC, Andersen PW, Astrup A, Buemann B, et al. (2004) Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study. Eur J Clin Nutr 58: 1062–1070.
[15]
Engler MM (2004) Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: Results from the early study. International Journal of Clinical Pharmacology and Therapeutics 42: 672679.
[16]
Prabodh Shah A (2007) Cardiovascular and endothelial effects of fish oil supplementation in healthy volunteers. Journal of Cardiovascular Pharmacology and Therapeutics 12: 213219.
[17]
Hill AM, Buckley JD, Murphy KJ, Howe PR (2007) Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am J Clin Nutr 85: 1267–1274.
[18]
Schiano V, Laurenzano E, Brevetti G, De Maio JI, Lanero S, et al. (2008) Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr 27: 241–247.
[19]
Mindrescu C, Gupta RP, Hermance EV, DeVoe MC, Soma VR, et al. (2008) Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia. Vasc Health Risk Manag 4: 1439–1447.
[20]
Wright SA, O'Prey FM, McHenry MT, Leahey WJ, Devine AB, et al. (2008) A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 67: 841–848.
[21]
Rizza S, Tesauro M, Cardillo C, Galli A, Iantorno M, et al. (2009) Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis 206: 569–574.
[22]
Stirban A, Nandrean S, Gotting C, Tamler R, Pop A, et al. (2010) Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr 91: 808–813.
[23]
Wong CY, Yiu KH, Li SW, Lee S, Tam S, et al. (2010) Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet Med 27: 54–60.
[24]
Hileman CO, Carman TL, Storer N, Harrill Labbato D, White C, et al.. (2011) Omega-3 fatty acids do not improve endothelial function in virologically-suppressed HIV-infected men: a randomized placebo-controlled trial. AIDS Res Hum Retroviruses.
[25]
Haberka M, Mizia-Stec K, Mizia M, Janowska J, Gieszczyk K, et al. (2011) N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction. Clin Nutr 30: 79–85.
[26]
Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR, et al. (2011) Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 93: 243–252.
[27]
Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, et al. (2011) Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. Am J Clin Nutr 94: 973–980.
[28]
Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, et al. (2011) Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin A double-blind, placebo-controlled, 3-arm study. Am Heart J 161: 915.e911–919.
[29]
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
[30]
Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. www.cochrane-handbook.org.
[31]
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609–613.
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
[34]
Di Minno MN, Tremoli E, Tufano A, Russolillo A, Lupoli R, et al. (2010) Exploring newer cardioprotective strategies: omega-3 fatty acids in perspective. Thromb Haemost 104: 664–680.
[35]
Wang Q, Liang X, Wang L, Lu X, Huang J, et al. (2012) Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis 221: 536–543.
[36]
Madonna R, De Caterina R (2011) Cellular and molecular mechanisms of vascular injury in diabetes–part I: pathways of vascular disease in diabetes. Vascul Pharmacol 54: 68–74.
[37]
Ponnuchamy B, Khalil RA (2009) Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol 296: R1001–1018.
[38]
Bornfeldt KE, Tabas I (2011) Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 14: 575–585.
[39]
Kromhout D, Giltay EJ, Geleijnse JM (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363: 2015–2026.
[40]
Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, et al. (2012) n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367: 309–318.
[41]
Kwak SM, Myung SK, Lee YJ, Seo HG (2012) Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized, Double-blind, Placebo-Controlled Trials. Arch Intern Med.
[42]
Hu FB, Manson JE (2012) Omega-3 Fatty Acids and Secondary Prevention of Cardiovascular Disease–Is It Just a Fish Tale?: Comment on “Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease”. Arch Intern Med.
[43]
Masoura C, Pitsavos C, Aznaouridis K, Skoumas I, Vlachopoulos C, et al. (2011) Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis 214: 129–138.
[44]
Shahin Y, Khan JA, Samuel N, Chetter I (2011) Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 216: 7–16.
